Leerink Partnrs Downgrades Bolt Biotherapeutics (NASDAQ:BOLT) to Hold

Leerink Partnrs cut shares of Bolt Biotherapeutics (NASDAQ:BOLT) from a strong-buy rating to a hold rating in a research report sent to investors on Tuesday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Bolt Biotherapeutics’ Q2 2024 earnings at ($0.39) EPS, Q3 2024 earnings at ($0.18) EPS, Q4 2024 earnings at ($0.18) EPS, FY2024 earnings at ($1.04) EPS, FY2025 earnings at ($0.74) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.16) EPS and FY2028 earnings at ($0.15) EPS.

A number of other equities analysts have also recently issued reports on the stock. SVB Leerink restated a market perform rating and set a $1.00 target price (down previously from $3.00) on shares of Bolt Biotherapeutics in a research report on Wednesday. Stifel Nicolaus restated a hold rating and issued a $1.50 target price (down from $6.00) on shares of Bolt Biotherapeutics in a report on Wednesday. HC Wainwright restated a neutral rating on shares of Bolt Biotherapeutics in a report on Wednesday. Finally, Guggenheim reiterated a neutral rating on shares of Bolt Biotherapeutics in a research note on Wednesday. Five investment analysts have rated the stock with a hold rating, According to data from MarketBeat.com, Bolt Biotherapeutics has a consensus rating of Hold and a consensus target price of $3.50.

Bolt Biotherapeutics Stock Down 3.9 %

Shares of NASDAQ:BOLT opened at $0.79 on Tuesday. The company has a quick ratio of 5.17, a current ratio of 5.68 and a debt-to-equity ratio of 0.16. Bolt Biotherapeutics has a fifty-two week low of $0.79 and a fifty-two week high of $2.03. The firm’s 50-day simple moving average is $1.18 and its 200-day simple moving average is $1.10. The company has a market cap of $30.23 million, a price-to-earnings ratio of -0.48 and a beta of 1.05.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.47) EPS for the quarter, meeting the consensus estimate of ($0.47). Bolt Biotherapeutics had a negative net margin of 556.59% and a negative return on equity of 51.74%. The firm had revenue of $2.09 million during the quarter, compared to analysts’ expectations of $1.97 million. As a group, equities research analysts predict that Bolt Biotherapeutics will post -1.68 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Bolt Biotherapeutics stock. Newtyn Management LLC grew its holdings in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 2.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,020,000 shares of the company’s stock after purchasing an additional 20,000 shares during the period. Newtyn Management LLC owned 2.69% of Bolt Biotherapeutics worth $1,061,000 as of its most recent SEC filing. Institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.